Take a closer look at OCREVUS for PPMS:

We invite you to learn more about why OCREVUS may be the right choice for treating your primary progressive multiple sclerosis (PPMS).

Shown to delay disability progression of PPMS

Results in lesion volume

Impacts walking speed

Learn how OCREVUS was studied in PPMS

Have fewer maybes

Proven to delay disability progression of PPMS

OCREVUS is the first and only FDA-approved treatment for PPMS proven in a clinical study to delay disability progression

*Disability progression was measured using a tool called the Expanded Disability Status Scale (EDSS). Disability progression was confirmed 3 months after the initial neurological worsening.
Disability progression was also confirmed after 6 months.

Important Safety Information

  • Infection:
    • OCREVUS increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or signs of herpes (such as cold sores, shingles, or genital sores). These signs can happen during treatment or after you have received your last dose of OCREVUS. If you have an active infection, your healthcare provider should delay your treatment with OCREVUS until your infection is gone.
    • Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with OCREVUS treatment in clinical trials, PML may happen with OCREVUS. PML is a rare brain infection that usually leads to death or severe disability.  Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs.
    • Hepatitis B virus (HBV) reactivation: Before starting treatment with OCREVUS, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS.
    • Weakened immune system: OCREVUS taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
OCREVUS® (ocrelizumab) and Results in Lesion Volume
Have fewer maybes

Proven superior results in lesion volume

OCREVUS reduced the volume of T2 hyperintense lesions, while T2 lesion volume increased in people taking placebo    

  • The average change in volume of T2 lesions was -0.39 cm3 for OCREVUS compared with 0.79 cm3 for placebo

OCREVUS was evaluated in a study including 732 people who were treated with OCREVUS or placebo for at least 120 weeks.

Have fewer maybes

Proven to impact walking speed

OCREVUS and walking speed

  • 49% of people taking OCREVUS and 59% of people taking placebo had a 20% decline on a walking speed test§

§Walking speed was confirmed at 3 months, over a 120-week period 

PPMS: Are you considering OCREVUS?

Download an education kit that can help you talk to your doctor about OCREVUS for PPMS.

Talk to your doctor about OCREVUS

Discover information and resources that can help you make the most of your next doctor's appointment.

Hear from a neurologist

Get an expert perspective. Watch Dr. Barry Hendin discuss OCREVUS and hear from patients on treatment.